Literature DB >> 11170978

Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml.

J P Ioannidis1, E J Abrams, A Ammann, M Bulterys, J J Goedert, L Gray, B T Korber, M J Mayaux, L M Mofenson, M L Newell, D E Shapiro, J P Teglas, C M Wilfert.   

Abstract

In a collaboration of 7 European and United States prospective studies, 44 cases of vertical human immunodeficiency virus type 1 (HIV-1) transmission were identified among 1202 women with RNA virus loads <1000 copies/mL at delivery or at the measurement closest to delivery. For mothers receiving antiretroviral treatment during pregnancy or at the time of delivery (or both), there was a 1.0% transmission rate (8 of 834; 95% confidence interval [CI], 0.4%-1.9%), compared with 9.8% (36 of 368; 95% CI, 7.0%-13.4%) for untreated mothers (risk ratio, 0.10; 95% CI, 0.05-0.21). In multivariate analysis adjusting for study, transmission was lower with antiretroviral treatment (odds ratio [OR], 0.10; P<.001), cesarean section (OR, 0.30; P=.022), greater birth weight (P=.003), and higher CD4 cell count (P=.039). In 12 of 44 cases, multiple RNA measurements were obtained during pregnancy or at the time of delivery or within 4 months after giving birth; in 10 of the 12 cases, the geometric mean virus load was >500 copies/mL. Perinatal HIV-1 transmission occurs in only 1% of treated women with RNA virus loads <1000 copies/mL and may be almost eliminated with antiretroviral prophylaxis accompanied by suppression of maternal viremia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11170978     DOI: 10.1086/318530

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  59 in total

1.  Aiming for zero: preventing mother-to-child transmission of HIV.

Authors:  Kathleen Steel O'Connor; Susan E MacDonald
Journal:  CMAJ       Date:  2002-04-02       Impact factor: 8.262

2.  Eligibility of overseas visitors and people of uncertain residential status for NHS treatment.

Authors:  Andrew J Pollard; Julian Savulescu
Journal:  BMJ       Date:  2004-08-07

3.  Viral sequence analysis from HIV-infected mothers and infants: molecular evolution, diversity, and risk factors for mother-to-child transmission.

Authors:  Philip L Bulterys; Sudeb C Dalai; David A Katzenstein
Journal:  Clin Perinatol       Date:  2010-12       Impact factor: 3.430

4.  Perinatal exposure to antiretroviral agents: risks and benefits.

Authors:  Gwendolyn B Scott
Journal:  AJNR Am J Neuroradiol       Date:  2005-04       Impact factor: 3.825

5.  Mother-to-child transmission of HIV: a global perspective.

Authors:  Katherine Luzuriaga
Journal:  Curr Infect Dis Rep       Date:  2007-11       Impact factor: 3.725

6.  Prenatal HIV tests. Routine testing or informed choice?

Authors:  Dale Guenter; Janusz Kaczorowski; June Carroll; John Sellors
Journal:  Can Fam Physician       Date:  2003-10       Impact factor: 3.275

7.  Screening HIV in pregnancy: a survey of prenatal care patients.

Authors:  Veronique Dorval; Kerri Ritchie; Andrée Gruslin
Journal:  Can J Public Health       Date:  2007 Sep-Oct

8.  Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants.

Authors:  Paige L Williams; Miguel Marino; Kathleen Malee; Susan Brogly; Michael D Hughes; Lynne M Mofenson
Journal:  Pediatrics       Date:  2010-01-18       Impact factor: 7.124

Review 9.  Treatment of HIV infection in pregnant women: antiretroviral management options.

Authors:  Mona R Loutfy; Sharon L Walmsley
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Kinetics and determining factors of the virologic response to antiretrovirals during pregnancy.

Authors:  Adriana Weinberg; Jeri E F Harwood; Elizabeth J McFarland; Jennifer Pappas; Jill Davies; Kay Kinzie; Emily Barr; Suzanne Paul; Carol Salbenblatt; Elizabeth Soda; Anna Vazquez; Charles A Peloquin; Myron J Levin
Journal:  Infect Dis Obstet Gynecol       Date:  2010-01-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.